We met with Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori) at ESMO 2019 to discuss the 3-year follow-up results from the phase III KEYNOTE-045 trial: Pembrolizumab Versus Investigator\u2019s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (NCT02256436).<\/p>\n

Questions<\/strong>
\n1. What are the limitations of the current standard of care for the second-line treatment of patients with recurrent urothelial cancer? (0:05<\/a>)
\n2. Could you tell us a little about the aims and design of the KEYNOTE-045 study? (3:44<\/a>)
\n3. What is the role of programmed death-ligand 1 (PD-L1) expression in predicting response? (6:02<\/a>)
\n4. What future studies of pembrolizumab in urothelial cancer are planned? (7:36<\/a>)<\/p>\n

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.<\/strong><\/p>\n

Speaker disclosure: Andrea Necchi has received honoraria from Roche, Merck, AstraZeneca, Janssen, and Foundation Medicine; has served as a consultant\/advisor for Merck Sharp & Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics\/Astellas, Bristol-Myers Squibb, and Rainier Therapeutics; has received institutional research funding from Merck Sharp & Dohme and AstraZeneca; has received travel expenses from Roche, Merck Sharp & Dohme, AstraZeneca, Janssen, and Rainier Therapeutics; and has an immediate family member who has other relationships with Bayer.<\/p>\n

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.<\/p>\n","protected":false},"excerpt":{"rendered":"

We met with Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori) at ESMO 2019 to discuss the 3-year follow-up results from the phase III KEYNOTE-045 trial: Pembrolizumab Versus Investigator\u2019s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (NCT02256436). Questions 1. What are the limitations of the current standard of care for the second-line […]<\/p>\n","protected":false},"featured_media":29598,"template":"","class_list":["post-29603","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-genitourinary-cancers","video_categories-esmo-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/29603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":0,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/29603\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/29598"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=29603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}